Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Advanced Melanoma

Journal Scan / Research · April 12, 2023

IFN-γ Signature Enables the Selection of Neoadjuvant Treatment in Patients With Stage III Melanoma

The Journal of Experimental Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Journal of Experimental Medicine
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
J Exp Med 2023 May 01;220(5)e20221952, ILM Reijers, D Rao, JM Versluis, AM Menzies, P Dimitriadis, MW Wouters, AJ Spillane, WMC Klop, A Broeks, LJW Bosch, M Lopez-Yurda, WJ van Houdt, RV Rawson, LG Grijpink-Ongering, M Gonzalez, S Cornelissen, J Bouwman, J Sanders, E Plasmeijer, YS Elshot, RA Scolyer, BA van de Wiel, DS Peeper, ACJ van Akkooi, GV Long, CU Blank

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading